Laurus Labs Part 2: Is it a Long term Investment Opportunity or a Value Trap or a Potential Default Candidate?
In my last post, I had pointed out some negative/positive points about the company. Currently, the company seems to be in a Capex mode as mentioned in my last post. The Q2FY24 results of the company was declared a few days ago. Below is the snapshot of the same. (Estimates of FY24 are assuming that the growth numbers in H1 FY24 will continue in H2FY24 and margins will remain on similar levels).
The QOQ situation has been better but the same cannot be
said for YOY. There are for more issues seen from the balance sheet of the
company. Days of receivables increased from 61 days in 2014 to 88 days in 2023.
Working Capital days also increased from 40 in 2014 to 86 in 2023. Reserves in
2014 were 277 crores which increased to 3918 crores in 2023. LT borrowings have
also increased from 188 crores to 761 crores in the same period. ST borrowings
have also increased from 312 crores to 996 crores in the same period. Based on
this an additional question arises that why are they increasing debt and not
using their reserves for any additional Capex or expenses that they might
incur.
Also when observing their shareholding pattern since 2017,
the following points are seen:
-
Promoter Stake reduced from 32% to 27% since
2019.
-
FII stake has increased from 10% to 24% but big
names like Amansa Holdings, Nomura, and Goldman Sachs have sold their stake.
-
DII stake has reduced from 44% to 11% since
2017.
-
Public Shareholding has increased from 16% to
38% since 2017. The number of shareholders have increased from 40,000 to 400000
since 2017.
Now when looking at the Conference Call of Q2FY24, they have
made the following statements (as compared to Q1FY24 Conference Call):
-
The company plans to spend approximately 1000
crores on capital expenditures in FY2024 out of which 385 crores has already
been incurred in H1FY24. This amount will cover the increase in the gross block
and capital work in progress, primarily directed towards ongoing expansion
projects in the CDMO/CMO businesses, and a new R&D centre. Laurus expects
to reap significant benefits from these investments starting from FY2025. (In
Q1FY24 they suggested that their Capex plans for FY24 are around 1700 crores.
This plan is for Greenfield & brownfield expansion of various projects. Out
of this, 300 crores will be financed via a term loan and 1400 crores from
internal accruals.)
-
New launches have been impacted due to delay in
regulatory approvals.
-
Excess channel inventory for ARV,
affecting its pricing.
-
In
FY2024, Europe business is expected to expand with higher volume of existing
products and new approvals from North America will trigger further growth.
-
Expecting
improved margins (due to higher revenues and cost saving measures) and higher
capacity utilization in H2FY24. (Margins are not being maintained since last 10
years which shows lot of variability in the profitability.)
Overall, the company has been investing heavily on its
R&D and future expansion and focused on increasing its non ARV segment for
which they have made lots of investments in manufacturing unit which has impacted
their capex and cash reserve. 70% of overall revenue comes from exports which
entitles them to high scrutiny and unpredictable tax regime along with high
inventories which is loss making. Forex exchange rate and increasing energy
prices (crude oil) impacted company’s overall efficiency and cash reserves.
However the company has been optimistic to gain fruits from current investment
from FY25 onwards.
Let us see if they are able to act on what they have been
suggesting in H1 FY24. Followup on this after Q3 results declared!!!
Happy Investing!!!!!
Comments
Post a Comment